The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer

International Journal of Cancer

Volumn 126, Issue 6, 2010, Pages 1417-1427

  Bijen, Claudia B M ^a   Bantema Joppe, Enja J ^a   De Jong, Renske A ^a   Leffers, Ninke ^a   Mourits, Marian J E ^a   Eggink, Henk F ^b   Van Der Zee, Ate G J ^a   Hollema, Harry ^a   De Bock, Geertruida H ^a   Nijman, Hans W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Public Health Service of Northern Friesland   (Netherlands)

Author keywords

2 microglobulin; Endometrial cancer; HLA G; MHC class I heavy chain

Indexed keywords

BETA 2 MICROGLOBULIN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER STAGING; CELL SURFACE; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS; UPREGULATION;

AGED; ANALYSIS OF VARIANCE; BETA 2-MICROGLOBULIN; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 74949117253     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24852     Document Type: Article

References (50)

1. Egli G, Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ, eds. Handbook of gynecologic oncology, 2nd edn. 2003, London: Martin Dunitz Ltd.
2. Werkgroep Oncologische Gynaecologie (WOG). Guideline endometrial carcinoma. Available at www.oncoline.nl. 2004. Accessed on October 2008.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
4. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450-6.
5. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008;14:2310-17.
6. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
7. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999;5:178-86.
8. Seliger B. Strategies of tumor immune evasion. BioDrugs 2005;19:347-54.
9. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001;19:1211-20.
10. Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007;13:3591-5.
11. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005;11:67-72.
12. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren G. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008;57:197-206.
13. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-3.
14. Kirszenbaum M, Djoulah S, Hors J, Prost S, Dausset J, Carosella ED. Polymorphism of HLA-G gene and protein. J Reprod Immunol 1999;43:105-9.
15. Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, Le Bouteiller P, Dohr G. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 1997;27:3380-8.
16. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 1996;156:4224-31.
17. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997;186:289-98.
18. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. H-LAG expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998;95:4510-15.
19. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000;48:17-26.
20. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble H-LAG protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001;98:12150-5.
21. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002;168:4772-80.
22. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11:1351-6.
23. Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001;13:193-201.
24. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007;14:2721-9.
25. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007;20:375-83.
26. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005;105:1694-8.
27. Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol 2006;103:25-30.
28. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
30. Goethals L, Perneel C, Debucquoy A, De SH, Borghys D, Ectors N, Geboes K, McBride WH, Haustermans KM. A new approach to the validation of tissue microarrays. J Pathol 2006;208:607-14.
31. Fons G, Hasibuan SM, van d V, ten Kate FJ. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 2007;60:500-3.
32. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171:1918-26.
33. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
34. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998;34:1334-40.
35. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008;57:1719-26.
36. Vermeulen CF, Jordanova ES, Zomerdijk-Nooijen YA, ter Haar NT, Peters AA, Fleuren GJ. Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum Immunol 2005;66:1167-73.
37. Garcia-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003;30:177-83.
38. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000;191:961-76.
39. Mattijssen V, De Mulder PH, Schalkwijk L, Manni JJ, 't Hof-Grootenboer B, Ruiter DJ. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991;6:95-100.
40. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006;24:178-86.
41. Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW. Expression of human leukocyte antigen-G and its correlation with interleukin-10 expression in cervical carcinoma. Int J Gynaecol Obstet 2007;98:48-53.
42. Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, Zhou MY. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol 2007;18:1804-9.
43. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F. Expression of HLA G in human tumors is not a frequent event. Int J Cancer 1999;81:512-18.
44. Frumento G, Franchello S, Palmisano GL, Nicotra MR, Giacomini P, Loke YW, Geraghty DE, Maio M, Manzo C, Natali PG, Ferrara GB. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment. Tissue Antigens 2000;56:30-7.
45. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003;81:199-252.
46. Leelawat K, Engprasert S, Pongchai-rerk U, Tuchinda S, Suthipintawong C, Leardkamolkarn V. No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells. J Med Assoc Thai 2004;87:816-18.
47. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Storkel S, Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004;109:265-73.
48. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;20(Suppl 4): A40-A45.
49. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003;4:525-36.
50. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001;61:6838-45.